IL-2 and TNF-α Levels, Number of Metastases, and Pain Score After 89SrCl2 Therapy
| After therapy | |||||||
|---|---|---|---|---|---|---|---|
| Parameter | Before therapy | 1 mo | 2 mo | 3 mo | 4 mo | 5 mo | 6 mo |
| IL-2 (ng/mL) | 2.87 ± 1.23 | 2.98 ± 0.54 | 3.14 ± 0.81 | 3.53 ± 1.01 | 4.13 ± 1.12 | 3.35 ± 0.96 | 2.94 ± 1.04 |
| TNF-α (ng/mL) | 2.77 ± 0.76 | 2.53 ± 0.14 | 2.01 ± 0.42 | 1.86 ± 0.21 | 1.49 ± 0.47 | 2.05 ± 0.26 | 2.76 ± 0.23 |
| No. of metastases | 12.16 ± 4.58 | 11.92 ± 4.12 | 10.87 ± 4.05 | 9.63 ± 3.11 | 9.05 ± 3.29 | 9.72 ± 4.00 | 10.39 ± 3.88 |
| Pain score | 8.24 ± 3.71 | 6.35 ± 3.04 | 5.84 ± 2.16 | 4.20 ± 3.87 | 3.99 ± 2.15 | 4.01 ± 3.64 | 4.73 ± 2.81 |
r = −0.91 for IL-2 lesions, −0.87 for IL-2 pain score, 0.78 for TNF-α lesions, and 0.62 for TNF-α pain score.